Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Junchao Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7878-8315; OpenAlex author ID A5017604963. Sources: OpenAlex.

Their work

Papers
46 (first author 2, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
96
Papers, trials and grants by year

2013: 3 papers · 2014: 4 papers · 2015: 1 paper · 2016: 1 paper · 2017: 3 papers · 2018: 4 papers · 2019: 4 papers · 2020: 6 papers · 2021: 8 papers · 2022: 3 papers · 2023: 1 paper · 2024: 5 papers · 2025: 3 papers

Papers 46

  1. NFE2-driven neutrophil polarization promotes pancreatic cancer liver metastasis progression. Last author DOI 10.1016/j.celrep.2024.115226↗
  2. NAMPT Modulates Gemcitabine Resistance in Pancreatic Cancer via the p53 Signaling Pathway. Last author DOI 10.1097/mpa.0000000000002468↗
  3. [Assessment of the predictive value of ultrasound imaging characteristics combined with clinical indicators for the prognosis of pancreatic ductal adenocarcino… Co-author DOI 10.3760/cma.j.cn112150-20241025-00850↗
  4. Development of a Serum-Based MicroRNA Signature for Early Detection of Pancreatic Cancer: A Multicenter Cohort Study. Co-author DOI 10.1007/s10620-024-08338-4↗
  5. Tumor microenvironment crosstalk between tumors and the nervous system in pancreatic cancer: Molecular mechanisms and clinical perspectives. Last author DOI 10.1016/j.bbcan.2023.189032↗
  6. Targeted inhibition of CHKα and mTOR in models of pancreatic ductal adenocarcinoma: A novel regimen for metastasis. Last author DOI 10.1016/j.canlet.2024.217280↗
  7. Obg-like ATPase 1 exacerbated gemcitabine drug resistance of pancreatic cancer. Co-author DOI 10.1016/j.isci.2024.110027↗
  8. Efficacy of color Doppler ultrasound and contrast-enhanced ultrasound in identifying vascular invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13244-024-01779-5↗
  9. Pancreatic ductal adenocarcinoma with synchronous and metachronous hepatic metastasis predicted by contrast-enhanced ultrasound. Co-author DOI 10.21037/qims-22-1132↗
  10. Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data. Co-author DOI 10.1016/j.neo.2022.100841↗
  11. FGFR3 Nuclear Translocation Contributes to Proliferative Potential and Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000002056↗
  12. Artificial intelligence in pancreatic cancer. Last author DOI 10.7150/thno.77949↗
  13. Comparison of minimal invasive versus open radical antegrade modular pancreatosplenectomy (RAMPS) for pancreatic ductal adenocarcinoma: a single center retrosp… Co-author DOI 10.1007/s00464-020-07938-1↗
  14. Radical antegrade modular pancreatosplenectomy (RAMPS) versus conventional distal pancreatosplenectomy (CDPS) for left-sided pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-020-02203-3↗
  15. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation. Co-author DOI 10.1007/s13238-020-00760-4↗
  16. Pancreatitis initiated pancreatic ductal adenocarcinoma: Pathophysiology explaining clinical evidence. Co-author DOI 10.1016/j.phrs.2021.105595↗
  17. Elevated TIAM2 expression promotes tumor progression and is associated with unfavorable prognosis in pancreatic cancer. Last author DOI 10.1080/00365521.2020.1853806↗
  18. Expression and Prognostic Value of Small Mothers Against Decapentaplegic 7, Matrix Metalloproteinase 2, and Matrix Metalloproteinase 9 in Resectable Pancreatic… Last author DOI 10.1097/mpa.0000000000001892↗
  19. Aerial View of the Association Between m6A-Related LncRNAs and Clinicopathological Characteristics of Pancreatic Cancer. Last author DOI 10.3389/fonc.2021.812785↗
  20. Prognostic stratification based on a novel nomogram for left-sided pancreatic adenocarcinoma after surgical resection: a multi-center study. Co-author PMID 34249426↗
  21. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Co-author DOI 10.1007/s00262-020-02542-7↗
  22. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study. Co-author DOI 10.1016/j.ebiom.2020.102767↗
  23. Photodynamic therapy of pancreatic cancer: Where have we come from and where are we going? Last author DOI 10.1016/j.pdpdt.2020.101876↗
  24. Matrix Metalloproteinase 11 as a Novel Tumor Promoter and Diagnostic and Prognostic Biomarker for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001583↗
  25. Transducin-Like Enhancer of Split-1 Inhibits Malignant Behaviors in vitro and Predicts a Better Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2020.00576↗
  26. Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review. Last author DOI 10.3389/fonc.2020.01466↗
  27. WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.02.043↗
  28. Clinicopathological and prognostic significance of MKK4 and MKK7 in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2018.11.026↗
  29. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41422-019-0195-y↗
  30. Research progress on circularRNAs in pancreatic cancer: emerging but promising. Last author DOI 10.1080/15384047.2019.1617563↗
  31. High nuclear Survivin expression as a poor prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.25253↗
  32. Tumor size classification of the 8th edition of TNM staging system is superior to that of the 7th edition in predicting the survival outcome of pancreatic canc… Co-author DOI 10.1038/s41598-018-28193-4↗
  33. PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay. Co-author DOI 10.1186/s13000-017-0678-4↗
  34. β1 and β3 integrins in breast, prostate and pancreatic cancer: A novel implication. First author DOI 10.3892/ol.2018.8076↗
  35. Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance. Co-author DOI 10.1016/j.canlet.2017.02.036↗
  36. Surgeons' knowledge regarding the diagnosis and management of pancreatic cancer in China: a cross-sectional study. Co-author DOI 10.1186/s12913-017-2345-6↗
  37. WT1-associated protein is a novel prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2017.5784↗
  38. Expression and Significances of MTSS1 in Pancreatic Cancer. Co-author DOI 10.1007/s12253-015-9963-2↗
  39. Nuclear translocation of fibroblast growth factor receptor 3 and its significance in pancreatic cancer. Co-author PMID 26823787↗
  40. N-wasp in pancreatic ductal adenocarcinoma: associations with perineural invasion and poor prognosis. Co-author DOI 10.1007/s00268-014-2500-8↗
  41. The prognostic value of Cyclin B1 in pancreatic cancer. Co-author DOI 10.1007/s12032-014-0107-4↗
  42. Prognostic significance of epidermal growth factor-like domain 7 in pancreatic cancer. Co-author DOI 10.1016/s1499-3872(14)60272-1↗
  43. [Application of miRNAs in the occurrence and early diagnosis of pancreatic cancer]. First author PMID 24785459↗
  44. Oligonucleotide microarray identifies genes differentially expressed during tumorigenesis of DMBA-induced pancreatic cancer in rats. Co-author DOI 10.1371/journal.pone.0082910↗
  45. [Expression of mitogen activated protein kinase phosphatase-1 in pancreatic cancer]. Co-author DOI 10.3881/j.issn.1000-503x.2013.06.011↗
  46. [The role of perioperative enteral and parenteral nutrition treatment in pancreatic cancer: a multicenter, prospective randomized controlled trial]. Co-author PMID 24444682↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Li Zhou · 23 shared papers, 2013–2024 · strength 2.13
  2. Jianzhou Liu · 8 shared papers, 2021–2025 · strength 1.62
  3. Jun Lü · 13 shared papers, 2017–2022 · strength 1.49
  4. Taiping Zhang · 18 shared papers, 2013–2022 · strength 1.43
  5. Zhiyong Liang · 13 shared papers, 2015–2025 · strength 1.39
  6. Gary Guishan Xiao · 7 shared papers, 2020–2025 · strength 1.29
  7. Lei You · 15 shared papers, 2014–2022 · strength 1.26
  8. Menghua Dai · 11 shared papers, 2013–2024 · strength 1.22
  9. Wenchao Xu · 5 shared papers, 2024–2025 · strength 1.17
  10. Bolun Jiang · 7 shared papers, 2020–2024 · strength 1.00
  11. Yu-Pei Zhao · 15 shared papers, 2013–2020 · strength 0.97
  12. Yupei Zhao · 8 shared papers, 2014–2021 · strength 0.78
  13. Qiaofei Liu · 5 shared papers, 2019–2025 · strength 0.76
  14. Quan Liao · 8 shared papers, 2017–2021 · strength 0.76
  15. Yizhi Wang · 5 shared papers, 2020–2021 · strength 0.65
  16. Bingqi Li · 6 shared papers, 2017–2019 · strength 0.54
  17. Yuejuan Cheng · 3 shared papers, 2022–2024 · strength 0.49
  18. Bowen Huang · 3 shared papers, 2021–2022 · strength 0.40
  19. Yizhi Wang · 3 shared papers, 2019–2022 · strength 0.39
  20. Wenming Wu · 5 shared papers, 2014–2021 · strength 0.36
  21. Jing Li Huang · 2 shared papers, 2024 · strength 0.36
  22. Vay Liang W. Go · 2 shared papers, 2024 · strength 0.36
  23. Dong Shang · 2 shared papers, 2021–2024 · strength 0.34
  24. Wan-Ying Jia · 2 shared papers, 2023–2024 · strength 0.33
  25. Zhigang Zhang · 3 shared papers, 2017–2024 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.